RT Journal Article
SR Electronic
T1 A population-based seroprevalence survey of severe acute respiratory syndrome coronavirus 2 infection in Beijing, China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.23.20197756
DO 10.1101/2020.09.23.20197756
A1 Wang, Xiaoli
A1 Gao, Wenjing
A1 Cui, Shujuan
A1 Zhang, Yi
A1 Zheng, Ke
A1 Ke, Ji
A1 Lv, Jun
A1 Yu, Canqing
A1 Sun, Dianjianyi
A1 Wang, Quanyi
A1 Li, Liming
YR 2020
UL http://medrxiv.org/content/early/2020/09/23/2020.09.23.20197756.abstract
AB BACKGOUND The spread of Coronavirus Disease 2019 (COVID-19) had been controlled in China. The seroprevalence of COVID-19 in Beijing has not been evaluated.METHODS In April, residents in Beijing were randomly enrolled. Blood samples were collected and antibodies to SARS- CoV-2 were tested by two colloidal gold kits. All colloidal gold positive serums were then tested by Micro- neutralization assay.RESULTS None of 2,184 residents participated was tested positive by micro-neutralization assay. The seroprevalence of COVID-19 in Beijing was estimated < 0.17%.CONCLUSIONS The seroprevalence of COVID-19 was low in April suggesting that community-wide spread was prevented in Beijing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis publication was supported by the National Natural Science Foundation of China (82041027), Special Research Fund of PKU for Prevention and Control of COVID-19 and the Fundamental Research Funds for the Central Universities.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study had been approved by the IRB at Peking University Health Science Center prior to participant enrollment (IRB00001052-20021).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available after the agreement of corresponding author.